Acadia Pharmaceuticals ACAD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $375.65M-3.9% | $391M+49.7% | $261.17M+17.6% | $222.16M-2.9% | $228.88M+1.1% | ||
| $913K+4.8% | $871K-2.7% | $895K+0.1% | $894K-1.4% | $907K-1.4% | ||
| $55.45M+6.4% | $52.14M+5.6% | $49.35M-20.8% | $62.33M-2.1% | $63.68M-5.0% | ||
| —— | —— | $198.95M+5.9% | $187.91M+26.1% | $148.96M-5.6% | ||
| $9.9M+111% | $4.69M+312% | $1.14M+38.8% | $820K— | —— | ||
| -$112.23M+62.9% | -$302.56M— | —— | —— | —— | ||
| $52.28M+4.8% | $49.88M+70.9% | $29.19M+45.7% | $20.03M+162% | $7.64M+11.6% | ||
| —— | —— | —— | —— | $15.95M-88.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Acadia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.